Clinical Trial

Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 2 study designed to evaluate the safety and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) or S-1 and oxaliplatin (SOX) in perioprative treatment of locally advanced MHC-II-negative gastric and gastroesophageal junction adenocarcinoma.
Trial Details
NCT Number NCT07325630
Lead Sponsor Zhejiang Cancer Hospital
Conditions IBI363 + Chemotherapy
Enrollment 60 participants
Start Date 2025-11-03
Primary Completion 2026-05-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-08